Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
J Wang, B Li, M Luo, J Huang, K Zhang… - Signal transduction and …, 2024 - nature.com
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …
Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
BRCA1 and BRCA2 play a critical role in a variety of molecular processes related to DNA
metabolism, including homologous recombination and mediating the replication stress …
metabolism, including homologous recombination and mediating the replication stress …
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Global estimates indicated 2.3 million new cases of breast cancer in 2020, contributing to
nearly 12% of all new cancer cases, with 685 000 deaths in the same year. 1 Breast cancer …
nearly 12% of all new cancer cases, with 685 000 deaths in the same year. 1 Breast cancer …
Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology
Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …
Germline genetic testing after cancer diagnosis
Importance Germline genetic testing is recommended by practice guidelines for patients
diagnosed with cancer to enable genetically targeted treatment and identify relatives who …
diagnosed with cancer to enable genetically targeted treatment and identify relatives who …
Current treatment landscape for early triple-negative breast cancer (TNBC)
Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is
characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant …
characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant …
[HTML][HTML] Understanding breast cancer complexity to improve patient outcomes: the St Gallen international consensus conference for the primary therapy of individuals …
The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna,
Austria, assessed significant new findings for local and systemic therapies for early breast …
Austria, assessed significant new findings for local and systemic therapies for early breast …
PARP inhibitors for breast cancer treatment: a review
Importance Poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitors have
revolutionized the treatment of patients with germlineBRCA1/2-associated breast cancer …
revolutionized the treatment of patients with germlineBRCA1/2-associated breast cancer …
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
B Arun, FJ Couch, J Abraham, N Tung… - British journal of …, 2024 - nature.com
Mutations in the BRCA1 and/or BRCA2 genes (BRCAm) increase the risk of develo**
breast cancer (BC) and are found in~ 5% of unselected patients with the disease. BC …
breast cancer (BC) and are found in~ 5% of unselected patients with the disease. BC …
Early-stage triple-negative breast cancer journey: beginning, end, and everything in between
Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast
cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early …
cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early …